Shares of OncoSec Medical Inc (NASDAQ:ONCS) have received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $2.83.

Several research analysts recently weighed in on the company. Maxim Group set a $5.00 target price on OncoSec Medical and gave the stock a “buy” rating in a research report on Thursday, November 29th. Zacks Investment Research raised OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Friday.

A number of large investors have recently added to or reduced their stakes in ONCS. BlackRock Inc. raised its position in OncoSec Medical by 98.2% in the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after purchasing an additional 240,843 shares during the period. Geode Capital Management LLC raised its position in OncoSec Medical by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 163,405 shares during the period. Bank of New York Mellon Corp raised its position in OncoSec Medical by 484.1% in the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 83,150 shares during the period. Northern Trust Corp raised its position in OncoSec Medical by 33.6% in the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 28,914 shares during the period. Finally, Moloney Securities Asset Management LLC raised its position in OncoSec Medical by 117.4% in the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 27,000 shares during the period. 6.41% of the stock is currently owned by institutional investors.

Shares of ONCS opened at $0.53 on Friday. OncoSec Medical has a twelve month low of $0.42 and a twelve month high of $2.21.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Friday, December 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06. Equities research analysts predict that OncoSec Medical will post -0.74 EPS for the current year.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

See Also: What type of investment options does a Roth IRA provide?

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.